Diffuse type gastric cancer is a highly invasive stomach cancer characterized by scattered cancer cells that infiltrate the stomach wall, making early detection difficult.
Understanding Diffuse Type Gastric Cancer
Diffuse type gastric cancer (DGC) is one of the two major histological subtypes of gastric adenocarcinoma, the other being the intestinal type. Unlike its intestinal counterpart, which forms gland-like structures, diffuse type gastric cancer lacks a cohesive architecture. Instead, it consists of poorly differentiated cells that infiltrate the stomach lining in a dispersed manner. This infiltrative growth pattern leads to thickening and stiffening of the stomach wall, a condition known as linitis plastica.
This subtype accounts for approximately 30-40% of all gastric cancers worldwide but is disproportionately represented in younger patients and females. Its elusive nature often results in diagnosis at advanced stages when symptoms become more pronounced. The diffuse spread through the stomach wall also means that tumors rarely form distinct masses, complicating both detection and surgical removal.
Pathophysiology and Cellular Characteristics
Diffuse type gastric cancer originates from the epithelial cells lining the stomach but diverges in its cellular behavior from other types. The hallmark of DGC is signet ring cells—cancer cells filled with mucin that push the nucleus to one side, giving them a ring-like appearance under a microscope. These cells lose adhesion molecules such as E-cadherin, which normally help cells stick together.
Loss of E-cadherin function is central to DGC’s aggressive nature. It promotes cell detachment and invasion into surrounding tissues without forming cohesive tumor masses. This molecular alteration facilitates early spread into the deeper layers of the stomach wall and beyond.
Genetic mutations play a significant role in DGC development. Germline mutations in the CDH1 gene coding for E-cadherin are strongly associated with hereditary diffuse gastric cancer syndrome (HDGC), which predisposes carriers to this aggressive cancer at a young age.
Molecular Alterations Driving Diffuse Type Gastric Cancer
- CDH1 mutations: Lead to loss of E-cadherin expression and cell adhesion.
- RHOA mutations: Affect cytoskeletal dynamics and promote motility.
- TP53 mutations: Common tumor suppressor gene alterations.
- Epigenetic changes: DNA methylation silences tumor suppressor genes.
These molecular features underscore why diffuse type gastric cancer behaves differently from intestinal types and why it resists conventional therapies targeting proliferative tumor masses.
Clinical Presentation and Diagnostic Challenges
The insidious nature of diffuse type gastric cancer means symptoms often emerge late and are nonspecific. Early on, patients might experience vague abdominal discomfort or indigestion that can be easily mistaken for benign conditions.
As DGC progresses, symptoms escalate to include:
- Persistent upper abdominal pain or discomfort
- Early satiety due to reduced stomach compliance
- Unexplained weight loss
- Nausea or vomiting
- Occult gastrointestinal bleeding leading to anemia
Because DGC infiltrates diffusely rather than forming discrete tumors, standard imaging techniques like CT scans or endoscopic visualization might miss early lesions or underestimate disease extent.
Diagnostic Modalities
Endoscopy with biopsy remains the cornerstone for diagnosis but requires multiple deep biopsies due to patchy infiltration patterns. Endoscopic ultrasound (EUS) can assess depth of invasion but may not detect scattered tumor cells effectively.
Advanced imaging such as PET scans offers limited sensitivity because diffuse tumors often have low metabolic activity compared to solid masses.
Histopathological examination confirms diagnosis by identifying signet ring cells and assessing tumor spread within the gastric wall layers.
Treatment Strategies for Diffuse Type Gastric Cancer
Treating diffuse type gastric cancer poses unique challenges due to its aggressive biology and tendency for widespread infiltration without clear margins.
Surgical Intervention
Surgery remains the primary curative approach for localized disease. However, total gastrectomy—removal of the entire stomach—is often necessary because partial resections risk leaving behind microscopic disease due to diffuse spread.
Lymphadenectomy (removal of regional lymph nodes) accompanies surgery since lymphatic spread occurs early in DGC.
Unfortunately, many patients present at advanced stages where surgery alone cannot achieve cure.
Chemotherapy and Targeted Therapies
Perioperative chemotherapy improves survival by shrinking tumors before surgery and eradicating micrometastases afterward. Regimens typically include platinum-based agents combined with fluoropyrimidines.
Targeted therapies have had limited success in DGC compared to intestinal types because common targets like HER2 overexpression are less frequent in diffuse cancers.
Research into agents targeting molecular pathways affected by CDH1 loss or RHOA mutations is ongoing but not yet standard practice.
Radiation Therapy
Radiotherapy plays a supportive role primarily in palliation or combined modality treatment but is rarely curative alone given DGC’s infiltrative pattern.
Prognosis and Survival Rates
Diffuse type gastric cancer generally carries a poorer prognosis than intestinal-type counterparts due to several factors:
- Late diagnosis at advanced stages
- High rates of lymph node involvement
- Difficulty achieving clear surgical margins
- Resistance to conventional chemotherapy
Five-year survival rates vary widely based on stage at diagnosis:
| Stage | Description | 5-Year Survival Rate (%) |
|---|---|---|
| I | Tumor confined to mucosa/submucosa; no nodal involvement | 60 – 80% |
| II & III | Tumor invades muscularis propria or serosa; nodal involvement present | 20 – 40% |
| IV | Distant metastasis present; advanced disease stage | <10% |
Early detection remains critical but challenging due to subtle symptomatology and diagnostic limitations inherent in diffuse growth patterns.
The Role of Genetics and Family History
Hereditary diffuse gastric cancer syndrome (HDGC) stems from inherited CDH1 mutations causing familial clustering of this aggressive subtype. Carriers face up to an 80% lifetime risk of developing DGC by age 80.
Genetic counseling is essential for families with multiple cases or early onset disease under age 40. Prophylactic total gastrectomy may be considered for mutation carriers even before symptoms arise due to high malignancy risk.
Testing for CDH1 mutations also guides surveillance strategies involving regular endoscopies with extensive biopsies aimed at catching microscopic changes early on.
Sporadic vs Hereditary Cases
While hereditary cases represent a minority, most DGC arises sporadically through accumulated somatic mutations influenced by environmental factors such as:
- Helicobacter pylori infection causing chronic inflammation
- Dietary factors including high salt intake and smoked foods
- Tobacco smoking
These elements synergize with genetic predispositions to trigger malignant transformation over time.
Differentiating Diffuse Type Gastric Cancer from Other Subtypes
The Lauren classification divides gastric adenocarcinoma into intestinal, diffuse, and mixed types based on histology. Distinguishing these subtypes matters because they differ significantly in clinical behavior, treatment response, and epidemiology.
| Feature | Intestinal Type | Diffuse Type | Mixed Type |
|---|---|---|---|
| Cellular architecture | Gland-forming | Poorly cohesive signet ring cells | Combination |
| Age group commonly affected | Older adults | Younger adults/females | Variable |
| Growth pattern | Expansive mass formation | Infiltrative thickening | Mixed features |
| Association with H.pylori | Strong | Less strong | Intermediate |
| Prognosis | Better | Poorer | Intermediate |
Understanding these distinctions helps clinicians tailor diagnostic approaches and therapeutic plans accordingly.
Key Takeaways: Diffuse Type Gastric Cancer
➤ Highly invasive: spreads widely through stomach walls.
➤ Poorly differentiated cells: lack gland formation.
➤ Signet ring cells: common histological feature.
➤ Associated with: CDH1 gene mutations.
➤ Poor prognosis: often diagnosed at advanced stages.
Frequently Asked Questions
What is diffuse type gastric cancer?
Diffuse type gastric cancer is a form of stomach cancer characterized by scattered, poorly differentiated cells that infiltrate the stomach wall. Unlike other types, it does not form distinct tumors but causes thickening and stiffening of the stomach lining.
How does diffuse type gastric cancer differ from intestinal type gastric cancer?
Diffuse type gastric cancer lacks gland-like structures seen in intestinal type. It consists of dispersed cancer cells that invade the stomach lining diffusely, making it harder to detect and treat early compared to the more cohesive intestinal subtype.
What are the cellular features of diffuse type gastric cancer?
This cancer subtype is marked by signet ring cells filled with mucin that push the nucleus to one side. These cells lose adhesion molecules like E-cadherin, allowing them to spread aggressively through the stomach wall without forming solid masses.
What genetic mutations are involved in diffuse type gastric cancer?
Mutations in the CDH1 gene, which codes for E-cadherin, are strongly linked to diffuse type gastric cancer. Other mutations include RHOA and TP53, as well as epigenetic changes that silence tumor suppressor genes, driving its aggressive behavior.
Why is early detection of diffuse type gastric cancer challenging?
The diffuse infiltration pattern leads to thickening rather than distinct tumors, making it difficult to identify with standard imaging or endoscopy. Symptoms often appear late, resulting in diagnosis at advanced stages when treatment options are limited.
Conclusion – Diffuse Type Gastric Cancer
Diffuse type gastric cancer stands out as an aggressive malignancy marked by scattered infiltration rather than discrete tumors. Its unique biology—driven largely by loss of cell adhesion molecules—results in late detection and poor outcomes compared to other gastric cancers. Though challenging diagnostically and therapeutically, advances in molecular genetics provide hope for improved screening strategies and targeted treatments tailored specifically for this elusive subtype. Vigilance through family history assessment, genetic testing when indicated, coupled with comprehensive clinical evaluation remains key to managing this formidable disease effectively.